Chester County News and Community Website
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) has provided an update on the U.S. commercial launch for OLINVYK (oliceridine) injection and announced anticipated milestones for 2021.
Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced the Company’s …
Read More CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced the publication …
Read More CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced that it has resubmitted …
Read More
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced publication of results …
Read More
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced publication of results from …
Read More
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, announced publication of APOLLO-2 (pivotal …
Read More
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System conditions, recently announced that it has initiated …
Read More
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN) announced the receipt of the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received …
Read More